{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T22:47:30Z","timestamp":1788648450027,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","onlinejacc.org","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.jacc.2017.05.063","type":"journal-article","created":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T18:55:50Z","timestamp":1500922550000},"page":"527-538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Cost-Effectiveness of Long-Term\u00a0Ticagrelor in Patients With Prior Myocardial Infarction"],"prefix":"10.1016","volume":"70","author":[{"given":"Elizabeth A.","family":"Magnuson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Vilain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Shafiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc P.","family":"Bonaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Storey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Braunwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2017.05.063_bib1","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/jama.2010.1322","article-title":"Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis","volume":"304","author":"Bhatt","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2017.05.063_bib2","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1093\/eurheartj\/ehq326","article-title":"Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study)","volume":"31","author":"Fox","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.05.063_bib3","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","article-title":"Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective","volume":"36","author":"Jernberg","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.05.063_bib4","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/j.1524-4733.2009.00529.x","article-title":"Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial","volume":"12","author":"Chen","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.jacc.2017.05.063_bib5","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jacc.2004.11.051","article-title":"Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation","volume":"45","author":"Weintraub","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.05.063_bib6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1161\/CIRCOUTCOMES.108.775247","article-title":"One-year\u00a0costs in patients with a history of or at risk for atherothrombosis in the United States","volume":"1","author":"Mahoney","year":"2008","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2017.05.063_bib7","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.05.063_bib8","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.05.063_bib9","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.05.063_bib10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jacc.2014.11.034","article-title":"Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study","volume":"65","author":"Cowper","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.05.063_bib11","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ahj.2005.02.044","article-title":"Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation","volume":"151","author":"Mahoney","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2017.05.063_bib12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1161\/CIRCULATIONAHA.109.900704","volume":"121","author":"Mahoney","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.05.063_bib13","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.05.063_bib14","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.05.063_bib15","first-page":"390","article-title":"Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials","volume":"37","author":"Udell","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.05.063_bib16","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ahj.2013.12.020","article-title":"Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial","volume":"167","author":"Bonaca","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2017.05.063_bib17","first-page":"1274","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"373","author":"Bonaca","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.05.063_bib18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00005650-200503000-00003","article-title":"US valuation of the EQ-5D health states: development and testing of the D1 valuation model","volume":"43","author":"Shaw","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.jacc.2017.05.063_bib19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/01621459.1987.10478410","article-title":"Better bootstrap confidence intervals","volume":"82","author":"Efron","year":"1987","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.jacc.2017.05.063_bib20","series-title":"Cost-Effectiveness in Health and Medicine","author":"Gold","year":"1996"},{"key":"10.1016\/j.jacc.2017.05.063_bib21","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.jacc.2014.03.016","article-title":"ACC\/AHA statement on cost\/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines","volume":"63","author":"Anderson","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.05.063_bib22","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","article-title":"Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease","volume":"67","author":"Bonaca","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.05.063_bib23","first-page":"400","article-title":"Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial","volume":"37","author":"Magnani","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.05.063_bib24","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.jacc.2016.03.529","article-title":"Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54","volume":"67","author":"Bhatt","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.05.063_bib25","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/eurheartj\/ehv531","article-title":"Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54","volume":"37","author":"Bonaca","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.05.063_bib26","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1161\/01.CIR.97.21.2129","article-title":"The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT: Multicenter Automatic Defibrillator Implantation Trial","volume":"97","author":"Mushlin","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.05.063_bib27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jacc.2015.10.046","article-title":"Cost-effectiveness of transcatheter aortic valve replacement with a self-expanding prosthesis versus surgical aortic valve replacement","volume":"67","author":"Reynolds","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.05.063_bib28","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1161\/CIRCULATIONAHA.111.054072","article-title":"Cost-effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis: results from the placement of aortic transcatheter valves (PARTNER) trial (Cohort B)","volume":"125","author":"Reynolds","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.05.063_bib29","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2165\/00019053-200826090-00009","article-title":"Subgroups and heterogeneity in cost-effectiveness analysis","volume":"26","author":"Sculpher","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jacc.2017.05.063_bib30","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jval.2013.01.013","article-title":"Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial","volume":"16","author":"Levin","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.jacc.2017.05.063_bib31","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.05.063_bib32","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2007.03.025","article-title":"Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial","volume":"49","author":"Bhatt","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.05.063_bib33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijcard.2015.08.058","article-title":"Impact of greater than 12-month dual antiplatelet therapy duration on mortality: drug-specific or a class-effect? A\u00a0meta-analysis","volume":"201","author":"Costa","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2017.05.063_bib34","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30\u00a0months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.05.063_bib35","doi-asserted-by":"crossref","first-page":"h1618","DOI":"10.1136\/bmj.h1618","article-title":"Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials","volume":"350","author":"Navarese","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2017.05.063_bib36","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.jacc.2015.03.003","article-title":"Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction","volume":"65","author":"Yeh","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.05.063_bib37","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1056\/NEJM199701303360503","article-title":"Scandinavian Simvastatin Survival Study Group. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease","volume":"336","author":"Johannesson","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.05.063_bib38","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1056\/NEJM199005313222201","article-title":"Platelet hyperreactivity and prognosis in survivors of myocardial infarction","volume":"322","author":"Trip","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.05.063_bib39","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jama.297.11.1197","article-title":"One-year cardiovascular event rates in outpatients with atherothrombosis","volume":"297","author":"Steg","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2017.05.063_bib40","unstructured":"NADAC (National Average Drug Acquisition\u00a0Cost). 2017. Available at: https:\/\/data.medicaid.gov\/Drug-Pricing-and-Payment\/NADAC-National-Average-Drug-Acquisition-Cost-\/a4y5-998d. Accessed April 5, 2017."}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109717376921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109717376921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T00:56:41Z","timestamp":1535590601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109717376921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0735109717376921"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2017.05.063","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Long-Term\u00a0Ticagrelor in Patients With Prior Myocardial Infarction","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2017.05.063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}